Abstract：
Gastrointestinal (GI) cancers have been considered primarily genetic malignancies, caused by a series of progressive genetic alterations. Accumulating evidence shows that histone methylation, an epigenetic modification program, plays an essential role in the different pathological stages of GI cancer progression, such as precancerous lesions, tumorigenesis, and tumor metastasis. Histone methylation-modifying enzymes, including histone methyltransferases (HMTs) and demethylases (HDMs), are the main executor of post-transcriptional modification. The abnormal expression of histone methylation-modifying enzymes characterizes GI cancers with complex pathogenesis and progression. Interactions between upstream controllers and histone methylation-modifying enzymes have recently been revealed, and have provided numerous opportunities to elucidate the pathogenesis of GI cancers in depth and clearly. Here we focus on the association between histone methylation-modifying enzymes and their controllers, aiming to provide a new perspective on the molecular research and clinical management of GI cancers.
摘要：
胃肠道（GI）癌症被认为主要是遗传性恶性肿瘤，由一系列渐进的遗传改变引起的。越来越多的证据表明组蛋白甲基化，表观遗传修饰计划，在胃肠道癌症进展的不同病理阶段中起着至关重要的作用，如癌前病变，肿瘤发生，和肿瘤转移。组蛋白甲基化修饰酶，包括组蛋白甲基转移酶（HMTs）和去甲基酶（HDMs），是转录后修饰的主要执行者。组蛋白甲基化修饰酶的异常表达表征具有复杂发病机制和进展的GI癌症。上游控制器和组蛋白甲基化修饰酶之间的相互作用最近被揭示，并提供了许多机会来深入和清楚地阐明胃肠道癌症的发病机制。在这里，我们专注于组蛋白甲基化修饰酶和它们的控制器之间的关联，旨在为胃肠道肿瘤的分子研究和临床管理提供新的视角。
